• Dual-Pathway Nanotherapy for Gefitinib Resistance

  2026-09-20

  Deng and colleagues developed a rational combination strategy that pairs gefitinib with crizotinib to suppress PI3K–AKT signaling and compensatory ERK activation in gefitinib-resistant lung adenocarcinoma. Integrated transcriptomics, phospho-proteomics, cell models, xenografts, zebrafish metastasis assays, and a dual-drug nanoparticle platform provide a multiscale framework for addressing both resistance and metastatic progression.

• Cepharanthine in Endometriosis: Organoid and In Vivo Evidenc

  2026-09-19

  A 2026 study evaluated Cepharanthine across immortalized stromal cells, patient-derived endometriotic cells, eutopic endometrial organoids, and a murine peritoneal model. Its central finding is that this biscoclaurine alkaloid suppresses lesion growth through cell-cycle arrest, DNA damage with impaired repair, and mitochondria-associated apoptosis, while also demonstrating the value of organoids for preclinical endometriosis research.

• iRhom2 in Olfaction: OR Regulation and Adaptation

  2026-09-18

  Azzopardi and colleagues identify iRhom2 as an olfactory sensory neuron regulator linked to odorant receptor expression and activity-dependent adaptation. Their combination of knockout-mouse transcriptomics, spatial validation, and heterologous receptor activation supports an iRhom2–ADAM17 signaling model while leaving several causal and translational questions open.

• Indometacin Sodium: Assay Workflows & Optimization

  2026-09-18

  Build reproducible inflammation, proliferation, oligodendrocyte differentiation, and pathway assays with Indometacin Sodium Trihydrate. This practical guide connects concentration selection, vehicle control, mechanistic readouts, and troubleshooting to help researchers distinguish COX-dependent effects from broader cellular responses.

• Danazol Assay Workflows for Endocrine Research

  2026-09-17

  This scenario-based guide explains how Danazol supports reproducible cell viability, steroidogenesis, and endocrine-model workflows. It connects mechanistic benchmarks with practical solvent, storage, control, and vendor-selection decisions for research use of SKU C3644.

• Angiotensin Peptides Enhance SARS-CoV-2 Binding

  2026-09-17

  Oliveira et al. show that naturally occurring angiotensin peptides can increase SARS-CoV-2 spike-protein binding to host receptors, with N-terminally truncated forms producing particularly strong effects. The study provides a mechanistic link between renin–angiotensin biology and viral receptor engagement while also defining important experimental limits: the evidence comes from binding assays rather than infection or clinical studies.

• X-Gal for Reproducible Reporter Workflows

  2026-09-16

  This scenario-based guide explains how X-Gal (SKU A2539) supports β-galactosidase reporter assays, blue-white colony screening, and molecular cloning while avoiding common interpretation errors in viability and cytotoxicity experiments. It covers substrate compatibility, stock handling, data interpretation, and practical vendor-selection criteria.

• Ang II–HIF-1α–HILPDA Axis in NPC Radioresistance

  2026-09-16

  This study identifies a local angiotensin II–AGT–HIF-1α–HILPDA circuit that suppresses ferroptosis and promotes radioresistance in nasopharyngeal carcinoma. Its combination of mechanistic cell biology, radiosensitivity assays, xenograft validation, and tissue analysis supports angiotensin II blockade plus ferroptosis induction as a strategy for further investigation.

• Biomimetic Microparticles Rewire Tumor pH for Therapy

  2026-09-15

  The ACS Nano study develops tumor cell-derived microparticles that co-deliver syrosingopine and a doxorubicin prodrug to disrupt both intracellular and extracellular pH homeostasis. By blocking lactate export, the platform links tumor metabolic stress to pH-dependent chemotherapy and partial restoration of antitumor immune activity.

• SB-505124 hydrochloride in Mechanobiology

  2026-09-15

  Use SB-505124 hydrochloride to separate TGF-β/activin-driven transcription from cancer-cell mechanics, fibroblast activation, and tissue remodeling. This workflow pairs pathway validation with stiffness measurements, viability controls, and model-specific interpretation.

• Patient-Derived Gastric Cancer Assembloids Explained

  2026-09-14

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine matched tumor organoids with tumor-derived stromal subpopulations. The model revealed that stromal composition changes transcriptional programs and drug sensitivity, supporting more physiologically relevant studies of tumor–microenvironment interactions and personalized treatment response.

• Indometacin Sodium: From COX to Remyelination

  2026-09-14

  Indometacin Sodium is more than a conventional COX inhibitor: it can help connect prostaglandin biology with Wnt/β-catenin-dependent oligodendrocyte repair. This guide explains how to design mechanistically discriminating assays around C6491 while separating established evidence from translational hypotheses.

• Dual HER2/VEGFR2 Targeting in TNBC Metastasis

  2026-09-13

  A 2026 study examined whether combining Lapatinib and Telatinib could suppress metastatic and angiogenic phenotypes in HER2-negative MDA-MB-231 triple-negative breast cancer cells. The work links reduced proliferation, invadopodia formation, and two-dimensional tube formation to a phenotype-first strategy for targeted cancer therapy research, while leaving direct target engagement and combination synergy unresolved.

• Organoid-Guided Therapy in Rare Neuroendocrine Cancer

  2026-09-12

  This 2026 reference study used longitudinal personalized tumor organoids and autologous tumor-infiltrating lymphocytes to map treatment response across the clinical course of a patient with chemoresistant neuroendocrine cervical cancer. Its main contribution is an integrated strategy that links organoid-guided drug discovery with immune co-culture and TIL optimization, suggesting a practical framework for individualized treatment selection in rare cancers.

• Prestained Protein Marker: F4005 Workflow Guide

  2026-09-11

  Learn how the Prestained Protein Marker (Triple color, EDTA free, 10-250 kDa), SKU F4005, can strengthen Western blot quality control alongside cell viability, proliferation, and cytotoxicity studies. This scenario-based guide covers compatibility, protocol handling, interpretation, and practical vendor selection.

7986 records 1/533 page Next 12345 下5页 Last page